Home » Stocks » KOD

Kodiak Sciences Inc. (KOD)

Stock Price: $145.91 USD -9.98 (-6.40%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Market Cap 7.41B
Revenue (ttm) n/a
Net Income (ttm) -102.13M
Shares Out 45.12M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $145.91
Previous Close $155.89
Change ($) -9.98
Change (%) -6.40%
Day's Open 156.81
Day's Range 144.52 - 158.13
Day's Volume 284,930
52-Week Range 38.18 - 164.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeu...

PRNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...

PRNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...

PRNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...

PRNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...

PRNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 12, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...

PRNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...

Zacks Investment Research - 2 months ago

Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

PRNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeu...

GuruFocus - 2 months ago

Biotech companies with IPOs of at least $50 million in the past three years have averaged an increase in share price of more than 42%. Gainers outpaced decliners by a ratio of two to one, acco...

Business Wire - 2 months ago

VANCOUVER, British Columbia & PALO ALTO, Calif.--(BUSINESS WIRE)---- $KOD #AbCellera--AbCellera and Kodiak Sciences Inc. (Nasdaq: KOD), today announced a new partnership to generate therapeuti...

The Motley Fool - 3 months ago

Despite recent run-ups, these two have what takes to keep rising.

Other stocks mentioned: ALGN
PRNewsWire - 3 months ago

PALO ALTO, Calif., Oct. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeu...

InvestorPlace - 4 months ago

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: ADAP, CCXI, MCRB, MYOV, NVAX, SRNE
Benzinga - 4 months ago

  Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.

Other stocks mentioned: KDP, XRX, CAR, GBDC, IGMS
Benzinga - 5 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: CAR, XRX, AXS, BH, JJSF, KMI, RRR
PRNewsWire - 5 months ago

PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc.

PRNewsWire - 6 months ago

PALO ALTO, Calif., July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc.

PRNewsWire - 6 months ago

PALO ALTO, Calif., July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-preval...

Zacks Investment Research - 7 months ago

Kodiak Sciences (KOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Kodiak Sciences

Seeking Alpha - 8 months ago

Kodiak Sciences Inc. (KOD) CEO Victor Perlroth on Q1 2020 Results - Earnings Call Transcript

Investopedia - 8 months ago

These are the small cap stocks with the best value, fastest growth, and most momentum for May.

Other stocks mentioned: TPH, XBIT
The Motley Fool - 9 months ago

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

Other stocks mentioned: AUPH, ZYME
Seeking Alpha - 9 months ago

Coronavirus Has Presented A Buying Opportunity In Kodiak Sciences

Investopedia - 10 months ago

These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q2 2020.

Other stocks mentioned: GLPG, LGND
Benzinga - 10 months ago

Kodiak Sciences Inc’s (NASDAQ: KOD) main drug candidate, KSI-301, highlights the company’s focus on innovation in a dynamic treatment landscape, according to Goldman Sachs.

24/7 Wall Street - 1 year ago

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...

Other stocks mentioned: CDMO, ENDP, IGMS, ILMN, ISEE, MYL, NVCN, PCRX, PFE, XFOR
The Motley Fool - 1 year ago

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, CNST, DRRX, EVER, ISEE, PRVB, RCEL, SSI
Seeking Alpha - 1 year ago

Kodiak Sciences: Stock That Skyrocketed In December

The Motley Fool - 1 year ago

These stocks have soared 935% or more this year. Can they keep the momentum going?

Other stocks mentioned: AXSM, CNST
The Motley Fool - 1 year ago

Here's why these drugmaker stocks are the year's top performers.

Other stocks mentioned: AXSM, CNST
Zacks Investment Research - 1 year ago

Is (KOD) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Does Kodiak Sciences Inc. (KOD) have what it takes to be a top stock pick for momentum investors?

Seeking Alpha - 1 year ago

Kodiak Sciences Fully Funded And Ready To Potentially Change Wet-AMD Treatment

The Motley Fool - 1 year ago

Helping people stricken with illness can be richly rewarding in more ways than one.

Other stocks mentioned: ARQL, ARWR, EIDX, GH, MEDP, NEO, NVRO, THC, ZTS
The Motley Fool - 1 year ago

These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?

Other stocks mentioned: AXSM, KRTX
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Kodiak Sciences.

Zacks Investment Research - 1 year ago

Kodiak Sciences Inc. (KOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The Motley Fool - 1 year ago

These stocks helped lead the markets higher.

Other stocks mentioned: CHK, PCG
The Motley Fool - 1 year ago

Momentum continues from the drugmaker's royalty deal announced earlier this week despite a big public stock offering.

The Motley Fool - 1 year ago

On a bad day on Wall Street, these stocks still held up well.

Other stocks mentioned: AKS, SRNE
InvestorPlace - 1 year ago

Kodiak Sciences (KOD) news about the company selling royalty rights for $225 million has KOD stock heading higher on Monday.

The Motley Fool - 1 year ago

Investors are excited about a big royalty deal for the biotech's lead pipeline candidate.

Zacks Investment Research - 1 year ago

Inside the best performing stocks of the Russell 2000 ETF.

Other stocks mentioned: ACHN, APPS, CFMS, EVER, IWM
The Motley Fool - 1 year ago

Despite soaring already, these biotech stocks aren't finished climbing.

Other stocks mentioned: AXSM, KRYS
Seeking Alpha - 1 year ago

Kodiak Sciences, Inc. (KOD) CEO Victor Perlroth on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

There's a pair of gems hiding in plain sight.

Other stocks mentioned: AXSM
The Motley Fool - 1 year ago

Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.

Other stocks mentioned: ADVM, RGNX

About KOD

Kodiak Sciences, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The c... [Read more...]

Industry
Biotechnology
IPO Date
Oct 4, 2018
CEO
Dr. Victor Perlroth
Employees
62
Stock Exchange
NASDAQ
Ticker Symbol
KOD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is 125.18, which is a decrease of -14.21% from the latest price.

Price Target
$125.18
(-14.21% downside)
Analyst Consensus: Buy